Protagonist Therapeutics (PTGX) Cash from Operations (2015 - 2026)

Protagonist Therapeutics has disclosed Cash from Operations across 12 years of filings, most recently posting 48943000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 48943000.0, down 139.04% year-over-year; the trailing twelve-month figure through Mar 2026 was 116635000.0 (down 134.62% YoY), and the FY2025 annual result was 57671000.0, down 68.68% from the prior year.
• Cash from Operations came in at 48943000.0 for Q1 2026 at Protagonist Therapeutics, down from 36975000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 268622000.0 in Q2 2024 to a low of 48943000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 27429000.0 (2024), against an average of 853352.94.
• Peak annual rise in Cash from Operations reached 1123.79% in 2024, while the deepest fall reached 272.04% in 2024.
• Protagonist Therapeutics' Cash from Operations stood at 31635000.0 in 2022, then soared by 153.61% to 16960000.0 in 2023, then tumbled by 272.04% to 29178000.0 in 2024, then retreated by 26.72% to 36975000.0 in 2025, then sank by 32.37% to 48943000.0 in 2026.
• The last three Cash from Operations figures came in at 48943000.0 (Q1 2026), 36975000.0 (Q4 2025), and 1937000.0 (Q3 2025), per Business Quant data.